Loading
Mochida Pharmaceutical Co.,Ltd.: what insiders have been doing
Insider filings for Mochida Pharmaceutical Co.,Ltd. are scarce in the EDINET (Japan FSA) feed, the latest one published on 10 April 2026. This page will fill in as new trades are disclosed. Source: insider filings from EDINET (Japan FSA). Past trades are no guide to future returns.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 9,010 of 24,148 companies
57.8
score / 100
Value53
Quality63
FCF yld-8.7%
Earn yld6.9%
EV/EBITDA8.8x
ROE6.8%
Gross mgn48%
Net mgn6.8%
Debt/EBITDA0.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
JP¥3,215
Analyst consensus
Income statement
RevenueJP¥117B
Gross profitJP¥56.3B48% margin
EBITDAJP¥14.2B12% margin
Net incomeJP¥7.9B7.5% margin
Valuation
PER (trailing)14.4x
P/Book0.8x
Beta0.09
Balance sheet & cash
Market capJP¥113.7B
Total debtJP¥10B
Free Cash Flow-JP¥10B
Debt / Equity7%
Profitability & ownership
ROE6.8%
ROA4.1%
% insiders36.3%
% institutions14.1%
Last declaration on 10 April 2026
Declarations2 total
ShareXTKSEDINET:S100XWLV
ShareXTKSEDINET:S100U3FO
2 of 2 declarations
About Mochida Pharmaceutical Co.,Ltd.
Mochida Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, and marketing of drugs. It focuses on therapeutic areas such as dermatology and neurology.